Thorac Cardiovasc Surg 2017; 65(S 01): S1-S110
DOI: 10.1055/s-0037-1598751
Oral Presentations
Sunday, February 12, 2017
DHTHG: Acquired Heart Valve Disease: Aortic Valve
Georg Thieme Verlag KG Stuttgart · New York

Bicuspid Aortic Valve-Sparing Root Surgery: What Is the Fate of Residual Aortic Regurgitation?

F.A. Kari
1   Cardiovascular Surgery, Heart Center Freiburg University, Freiburg, Germany
,
D. Richardt
2   Cardiac and Thoracic Vascular Surgery, University Heart Center Lübeck, Lübeck, Germany
,
F. Beyersdorf
1   Cardiovascular Surgery, Heart Center Freiburg University, Freiburg, Germany
,
N. Doll
3   Cardiac Surgery, Sana Cardiac Surgery, Stuttgart, Germany
,
W. Hemmer
3   Cardiac Surgery, Sana Cardiac Surgery, Stuttgart, Germany
,
M. Liebrich
3   Cardiac Surgery, Sana Cardiac Surgery, Stuttgart, Germany
,
H. Reichenspurner
4   Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
C. Detter
4   Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
,
H.H. Sievers
2   Cardiac and Thoracic Vascular Surgery, University Heart Center Lübeck, Lübeck, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
03 February 2017 (online)

 

    Objectives: To investigate the incidence and fate of bicuspid aortic valves (BAV) with mild residual aortic regurgitation (AR) mid-term after valve-sparing aortic root replacement (V-SARR) in a retrospective multicenter cohort.

    Methods: Between 1994 and 2014, a total of 163 BAV patients (144 males, 44 ± 13 years of age) underwent V-SARR at four aortic surgical centers for AR and/or aortic aneurysm. Combined retrospective data analysis was focused on progression of residual AR and reoperation rates on the aortic valve. Time-related endpoints were analyzed using Kaplan Meier and Log Rank calculations. Average follow-up time was 5 years, cumulating in 445 patient-years.

    Results: The majority of 141 patients (86%) underwent a David I procedure with straight tube graft, while 21 (14%) were treated using a David II/Yacoub remodeling operation. Mean prosthesis size used was 30 ± 2 mm. Average AR grade was 2.0 preoperatively, while it was 0.4 directly postoperatively and progressed to 0.6 at latest follow-up. The incidence of mild residual AR directly after V-SARR was 29% (47 patients). The incidence of reoperation on the aortic valve was 6% (10 patients). Only two of the reoperated patients had left the operating room with residual AR. Mild residual AR progressed in 23% of cases. Freedom from reoperation was 94%. In the patients in need of reoperation, the spared BAV had lasted for an average of 9.8 years (median 10.1 years) before valve replacement became necessary.

    Conclusion: V-SARR for BAV provides patients with a long time of living without anticoagulation before replacement becomes necessary. Mild residual AR progresses sub-clinically within the first 5 years, and is not a good indicator of need of reoperation in these patients.


    #

    No conflict of interest has been declared by the author(s).